New mapping tech aims to sharpen heart ablation for AFib

NCT ID NCT06701292

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study was designed to test a new, more targeted way to perform ablation for atrial fibrillation (AFib). Instead of burning a wide area around the pulmonary veins, doctors would use special mapping technology to precisely target the heart muscle sleeves causing the abnormal signals. The study planned to compare this new method to the standard wide-area approach in people with symptomatic paroxysmal AFib, but it was withdrawn before enrolling any participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Radiofrequency ablation with omnipolar mapping technology

What this could lead to

If successful, this could lead to a more precise and efficient ablation procedure for atrial fibrillation, potentially reducing procedure time and improving outcomes.

What could go wrong

This is a very early pilot study with no enrolled participants, so results are unknown. The new technique may not be better than standard ablation and could carry similar risks like bleeding or heart rhythm issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Texas Health Science Center at Houston

    Houston, Texas, 77030, United States